Differences in the populations studied could account for these discrepancies. In a previous study, we found that anti-HIV negative homosexuals with chronic hepatitis B seemed to respond as frequently as heterosexuals to ARA AMP treatment.3 In the same study, we found retrospectively that a low level of hepatitis B virus replication, as reflected by low serum hepatitis B virus DNA concentrations, was a factor for predicting response to ARA AMP.
Differences in the populations studied could account for these discrepancies. In a previous study, we found that anti-HIV negative homosexuals with chronic hepatitis B seemed to respond as frequently as heterosexuals to ARA AMP treatment.3 In the same study, we found retrospectively that a low level of hepatitis B virus replication, as reflected by low serum hepatitis B virus DNA concentrations, was a factor for predicting response to ARA AMP.
The aims of this study were to assess, in patients with chronic hepatitis B: (a) the response to ARA AMP according to the pretreatment concentration of serum hepatitis B virus DNA, (b) the kinetics of the antiviral effect of ARA AMP as assessed by a quantitative method, and (c) the efficacy of a second course of ARA AMP given six months after a first ineffective course.
Methods

PATIENTS
Sixty patients (aged 18-75) with chronic hepatitis B were enrolled in this multicentre trial. Entry criteria were (a) presence of HBsAg in serum for more than one year; (b) presence of HBeAg and absence of antiHBe antibodies; (c) increased activities of serum alanine aminotransferase (ALT) with stable values assessed three times within the six months before inclusion (less than 50% change); ( 
Results
Nineteen of 60 patients (32%) included in our study were homosexuals. Before ARA AMP administration, 10 patients (17%) had serum hepatitis B virus DNA concentrations higher than 200 pg/ml; 26 patients (43%) had serum ALT activities below three times the upper limit of normal and seven patients (12%) had cirrhosis.
There were no significant differences between low and high replication groups for age, weight, sex ratio, proportion of homosexuals, known duration of hepatitis B virus infection, serum ALT activities, serum albumin, plasma prothrombin, and presence of cirrhosis (Table I ). Mean serum hepatitis B virus DNA concentrations were 42 (26) pg/ml and 227 (182) pg/ml in patients with low and high replication, respectively. During the study, one patient dropped out seven days after the start of ARA AMP and treatment was withdrawn in nine patients because of side effects (eight for myalgia and one for vomiting). These 10 patients (five in the high replication group and five in the low replication group) were considered non-responders. EFFECT (Fig 1) . Pretreatment serum ALT activities were higher in the five patients with HBeAg to antiHBe seroconversion after ARA AMP administration than in the other patients (321 (234) IU/ml v 173 (124) IU/ml, p<0O05).
KINETICS STUDY
The kinetics study of serum hepatitis B virus DNA was performed in 30 patients, and showed a significant decrease during ARA AMP administration (Fig 2) It is important to note that HBsAg to antiHBs seroconversion occurred in two higher hepatitis B virus DNA concentrations patients in this study (3.3%/o). In these two and lower serum ALT activities than patients patients, complete inhibition of hepatitis B previously referred to our centre. Indeed, in virus replication was confirmed by disappearour previous study, we found that patients with ance of serum hepatitis B virus DNA, as high hepatitis B virus DNA concentrations and assessed by polymerase chain reaction.' 0 This low serum ALT activity had a lower rate of result is not different from the 3-7% rate of response than other patients.3 In a recent trial HBsAg to antiHBs seroconversion seen in with recombinant alpha interferon performed some alpha interferon studies." 12 This result after this ARA AMP trial, we also saw a is lower, however, than that reported by comparatively low rate of HBeAg to antiHBe Alexander et al 13 who showed the disappearseroconversion (23%) (unpublished data). ance of HBsAg in 22% and the appearance of Although this study showed a lower rate of HBs antibody in 13% of patients. This result complete response with ARA AMP treatment shows that ARA AMP, like alpha interferon, than is usually seen with alpha interferon, ARA may result in a complete inhibition of hepatitis AMP should be considered in the treatment of B virus replication. chronic hepatitis B in patients who do not No significant increase of serum ALT activrespond to, who develop side effects to, or who ity was seen in most patients during or after have contraindications to, alpha interferon. In ARA AMP administration. A mild increase of particular, ARA AMP might be useful in the serum ALT was seen in two of five responders treatment of patients who have had a liver or but no appreciable increase of serum ALT was kidney transplant in whom alpha interferon seen in any patient with HBe seroconversion as might increase the risk of rejection.8 9 usually seen in patients responding to alpha The kinetics and the relative magnitude of interferon. This finding illustrates that ARA the decrease of serum hepatitis B virus DNA AMP acts in chronic hepatitis B by an excluwas similar in patients with low and high repli-sive antiviral effect and that, in contrast with cation (Fig 3) . A sustained effect, however, alpha interferon, an increase of hepatocytic was only obtained in patients with a low necrosis is rarely seen. pretreatment value of serum hepatitis B virus
The kinetics of serum hepatitis B virus DNA DNA concentration (in whom a more com-in our patients with chronic hepatitis B plete viral inhibition was probably reached). confirms an inhibition of hepatitis B virus replication, which is rapid and considerable but usually transient. neuropathy related to an accidental overdose of ARA AMP administration as previously described.'6 As neurotoxicity depends on the length of the treatment'4 and as the fourth week of treatment does not improve the antiviral effect, a three week course should be considered. A second course of ARA AMP induced seroconversion from HBeAg to antiHBe in only one of the 32 retreated patients. This result is not in agreement with the 67% rate of HBe seroconversion seen in another study. '6 This discrepancy might be related to the level of hepatitis B virus replication before treatment, which might have been lower in the patients in the study by Trepo et al. Indeed, the only responder to a second course of ARA AMP had a sustained lowering of hepatitis B virus DNA after the first course and had a low serum hepatitis B virus DNA concentration (below 50 pgfml) before the second course of ARA AMP. Our results show that a second course does not seem to improve the rate of response to ARA AMP.
In conclusion, ARA AMP induces a considerable but transient antiviral effect on hepatitis B virus. A complete and sustained inhibition of hepatitis B virus replication with this substance is rare, and only obtained in patients with low hepatitis B virus replication.
